Inhibikase Therapeutics Inc
IKT1.645USD
-0.075-4.36%
Market hours （ET）Quotes delayed by 15 min
123.06MMarket Cap
3.49P/E TTM
More Details of Inhibikase Therapeutics Inc Company
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
Inhibikase Therapeutics Inc Info
Ticker SymbolIKT
Company nameInhibikase Therapeutics Inc
IPO dateDec 23, 2020
CEOIwicki (Mark T)
Number of employees15
Security typeOrdinary Share
Fiscal year-endDec 23
Address1000 N. West Street, Suite 1200
CityWILMINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19801
Phone13022953800
Websitehttps://www.inhibikase.com/
Ticker SymbolIKT
IPO dateDec 23, 2020
CEOIwicki (Mark T)
Company Executives of Inhibikase Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Roberto Bellini
Mr. Roberto Bellini
Independent Director
Independent Director
1.46M
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
893.54K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
431.81K
--
Mr. Arvind Kush
Mr. Arvind Kush
Independent Director
Independent Director
145.00K
--
Mr. David Mcintyre
Mr. David Mcintyre
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
10.29K
--
Dr. John Adams, Ph.D.
Dr. John Adams, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Timothy (Tim) Pigot
Mr. Timothy (Tim) Pigot
Chief Commercial and Strategy Officer
Chief Commercial and Strategy Officer
--
--
Mr. Dennis N. Berman
Mr. Dennis N. Berman
Independent Director
Independent Director
--
--
Dr. Roy Freeman, M.D.
Dr. Roy Freeman, M.D.
Independent Director
Independent Director
--
--
Mr. Mike Moyer
Mr. Mike Moyer
Managing Director of LifeSci Advisors
Managing Director of LifeSci Advisors
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Roberto Bellini
Mr. Roberto Bellini
Independent Director
Independent Director
1.46M
--
Mr. Vincent E. (Vince) Aurentz
Mr. Vincent E. (Vince) Aurentz
Independent Director
Independent Director
893.54K
--
Mr. Amit D. Munshi
Mr. Amit D. Munshi
Independent Chairman of the Board
Independent Chairman of the Board
431.81K
--
Mr. Arvind Kush
Mr. Arvind Kush
Independent Director
Independent Director
145.00K
--
Mr. David Mcintyre
Mr. David Mcintyre
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
10.29K
--
Dr. John Adams, Ph.D.
Dr. John Adams, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sands Capital Ventures LLC
10.77%
Soleus Capital Management, L.P.
5.23%
Fairmount Funds Management LLC
5.07%
SP IKT Holdings LLC
4.83%
Perceptive Advisors LLC
4.48%
Other
69.62%
Shareholders
Shareholders
Proportion
Sands Capital Ventures LLC
10.77%
Soleus Capital Management, L.P.
5.23%
Fairmount Funds Management LLC
5.07%
SP IKT Holdings LLC
4.83%
Perceptive Advisors LLC
4.48%
Other
69.62%
Shareholder Types
Shareholders
Proportion
Hedge Fund
31.76%
Investment Advisor
5.84%
Investment Advisor/Hedge Fund
4.85%
Corporation
4.83%
Private Equity
4.48%
Individual Investor
3.18%
Research Firm
0.24%
Bank and Trust
0.06%
Pension Fund
0.04%
Other
44.72%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
110
54.77M
73.50%
+878.44K
2025Q2
87
62.36M
83.88%
+6.72M
2025Q1
82
60.21M
81.40%
+7.53M
2024Q4
61
58.78M
83.36%
+15.59M
2024Q3
38
1.99M
24.34%
-203.16K
2024Q2
42
2.13M
28.26%
+379.22K
2024Q1
47
1.51M
21.65%
-625.47K
2023Q4
49
1.53M
25.68%
-638.36K
2023Q3
54
2.02M
35.52%
-749.23K
2023Q2
55
2.34M
41.60%
-408.30K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sands Capital Ventures LLC
10.95M
14.69%
--
--
Jun 30, 2025
Soleus Capital Management, L.P.
6.33M
8.49%
--
--
Jun 30, 2025
Fairmount Funds Management LLC
6.13M
8.22%
--
--
Jun 30, 2025
SP IKT Holdings LLC
5.84M
7.84%
+5.84M
--
Oct 21, 2024
Perceptive Advisors LLC
5.43M
7.29%
-492.71K
-8.32%
Jun 30, 2025
Commodore Capital LP
5.40M
7.24%
+53.06K
+0.99%
Jun 30, 2025
Adar1 Capital Management LLC
5.12M
6.87%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
3.22M
4.33%
+375.71K
+13.19%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.43M
3.25%
+2.08M
+608.12%
Jun 30, 2025
Blackstone Alternative Asset Management, L.P.
2.64M
3.54%
+567.59K
+27.41%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Micro-Cap ETF
Proportion0.02%
iShares Russell 2000 Value ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 29, 2023
Merger
6→1
Jun 29, 2023
Merger
6→1
Jun 29, 2023
Merger
6→1
Jun 29, 2023
Merger
6→1
Date
Type
Ratio
Jun 29, 2023
Merger
6→1
Jun 29, 2023
Merger
6→1
Jun 29, 2023
Merger
6→1
Jun 29, 2023
Merger
6→1
FAQs
Who are the top five shareholders of Inhibikase Therapeutics Inc?
The top five shareholders of Inhibikase Therapeutics Inc are:
Sands Capital Ventures LLC holds 10.95M shares, accounting for 14.69% of the total shares.
Soleus Capital Management, L.P. holds 6.33M shares, accounting for 8.49% of the total shares.
Fairmount Funds Management LLC holds 6.13M shares, accounting for 8.22% of the total shares.
SP IKT Holdings LLC holds 5.84M shares, accounting for 7.84% of the total shares.
Perceptive Advisors LLC holds 5.43M shares, accounting for 7.29% of the total shares.
Sands Capital Ventures LLC holds 10.95M shares, accounting for 14.69% of the total shares.
Soleus Capital Management, L.P. holds 6.33M shares, accounting for 8.49% of the total shares.
Fairmount Funds Management LLC holds 6.13M shares, accounting for 8.22% of the total shares.
SP IKT Holdings LLC holds 5.84M shares, accounting for 7.84% of the total shares.
Perceptive Advisors LLC holds 5.43M shares, accounting for 7.29% of the total shares.
What are the top three shareholder types of Inhibikase Therapeutics Inc?
The top three shareholder types of Inhibikase Therapeutics Inc are:
Sands Capital Ventures LLC
Soleus Capital Management, L.P.
Fairmount Funds Management LLC
Sands Capital Ventures LLC
Soleus Capital Management, L.P.
Fairmount Funds Management LLC
How many institutions hold shares of Inhibikase Therapeutics Inc (IKT)?
As of 2025Q3, 110 institutions hold shares of Inhibikase Therapeutics Inc, with a combined market value of approximately 54.77M, accounting for 73.50% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -10.38%.
What is the biggest source of revenue for Inhibikase Therapeutics Inc?
In --, the -- business generated the highest revenue for Inhibikase Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
